Promoting Real-World Clinical Adoption and Utilization of Solutions Through Joint Research
Huron, a medical artificial intelligence (AI) company specializing in neurological diseases, announced on the 25th that it has recruited Professor Chan Ling Ling, a Parkinson's disease authority at Singapore General Hospital, as a medical advisory board member.
Professor Chan Ling Ling is a world-renowned scholar in neuro-head and neck radiology. She has shown particular prominence in Parkinson's disease research. She currently serves as a Senior Consultant and Clinical Scientist at Singapore General Hospital, a Professor at Duke-NUS Medical School, and Deputy Chair of Research at the SingHealth-Duke-NUS Academic Medical Centre.
Professor Chan has published over 200 research papers and is recognized as an outstanding researcher and physician in academia, with an H-index of 37, reflecting her scholarly achievements and influence.
Before joining as an advisory board member, Professor Chan personally used and experienced Huron's Parkinson's disease solutions, HuronIPD and HuronNI, acknowledging their value. She has also conducted numerous studies utilizing Huron's solutions, supporting Huron's research and development and the clinical potential of the solutions.
On the 13th, she participated as a speaker at Huron's 'Parkinson Leaders Forum,' presenting "Nigrosome 1 Imaging at Singapore General Hospital and Experience with Huron Parkinson Solutions" to domestic neurology and radiology medical staff.
Going forward, Huron plans to further develop its Parkinson's disease solution products based on Professor Chan's extensive research and patient imaging diagnostic experience, publish more studies and papers through joint research, and promote the actual clinical adoption and utilization of the solutions.
Since obtaining Singapore regulatory approval for HuronIPD in February this year, Huron has been accelerating its entry into the Southeast Asian market. Additionally, in collaboration with Professor Chan, Huron is focusing on clinical evidence research to enter Singapore's insurance reimbursement system, aiming to expand adoption in broader global markets based on this foundation.
CEO Donghoon Shin said, "We are honored to recruit Professor Chan Ling Ling, recognized as a world authority, as an advisory board member for Huron's Parkinson's disease solutions. This recruitment is an important opportunity for Huron's solutions to take a leap forward. We will do our best to generate the best synergy by conducting high-quality research together based on Professor Chan's outstanding research capabilities and experience."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
